In short. Blood spun to concentrate platelets, injected as a biologic rather than supplied as a product, and reabsorbed after a short period.
Key points
- Where there is no product label, the method is the only description of what is being injected.
- That makes the method answerable, and it means a claim about the treatment is a claim about a material that has not been defined in a way anybody else has to follow.
Platelet-rich plasma is a preparation made from a person’s own blood and injected as a biologic. What kind of object it is explains most of what can and cannot be known about it.
A preparation rather than a product
Blood is drawn and separated so that the platelets concentrate into a layer, and the resulting preparation is used in the same session. An anticoagulant is added so that the blood does not clot during the process, which is the difference between this and a fibrin preparation. What is in the syringe is not a defined substance with a batch number and a release specification; it is the output of a process, and the process varies.
What determines the composition
The kit, the device that spins it, the speed and duration of the spin, and the interval between drawing the blood and injecting it all affect the result. None of these is standardised between clinics. The consequence is not that one clinic is careless and another careful; it is that two treatments carrying the same name are not the same material, and a concentration stated in a brochure describes one clinic’s protocol rather than an outcome.
The process is the specification
Where there is no product label, the method is the only description of what is being injected. That makes the method answerable, and it means a claim about the treatment is a claim about a material that has not been defined in a way anybody else has to follow.
It is reabsorbed
The preparation does not remain in the tissue as a filler does. It is broken down and cleared over a short period, which means any volume it provides is temporary and any effect that outlasts it has to be explained by the response it provoked rather than by its continued presence. That is worth understanding before treatment rather than after, because a person expecting a lasting change in shape has misunderstood what is being injected.
What it is not
It is not an approved cosmetic treatment, so no authority has assessed the claim made for it. It is not a filler, so it does not restore volume in the way a defined material does. It is not standardised, so two clinics are not necessarily offering the same substance. And it is not risk-free, even though the material comes from the person receiving it, because removing the risk of donor transmission does not remove the risk of what happens during preparation.
Three questions worth asking about the material
- How is the preparation made here, and how long passes between drawing the blood and injecting it?
- What is it expected to do that another option would not, and on what evidence is that expectation based?
- How many sessions are being proposed, and what happens if the first few change nothing?
Answering those turns a name into a description of a process and a plan, which is the only form in which the treatment can be weighed.
Frequently asked questions
What is platelet-rich plasma made of?
Blood drawn from the person receiving it, separated with an added anticoagulant so that the platelets concentrate into a layer, and used in the same session. It is a preparation rather than a product, and what is in the syringe depends on the kit, the device and the spin used to make it.
How is it different from platelet-rich fibrin?
The preparation. A fibrin preparation coagulates without an added anticoagulant and forms a fibrin network; this one is separated with an anticoagulant and remains a liquid concentrate. They are different materials produced by different processes, and a statement about one is not a statement about the other.
Is it a product with an approval?
No. It holds no cosmetic approval, because a preparation made at the point of care from the patient's own blood is a process rather than a product, and product authorisation attaches to products. The devices used are regulated separately, as laboratory equipment.
Risks & Limitations
- There is no cosmetic approval, and no authority has assessed the claims made for the treatment.
- The platelet concentration depends on the kit, device and spin used, and is not standardised or comparable between clinics.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- Adding it to another treatment is not evidence that the combination works better than the main treatment alone.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet-rich plasma for hair loss and skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.